Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Newsoara Expands In-Licensed Territory for BET Inhibitor to Asia

publication date: Nov 15, 2021

Newsoara Biopharma of Shanghai expanded its partnership with Zenith Epigenetics for a BET inhibitor to include Asia, India and ten Eurasian countries. In 2019, Newsoara acquired greater China rights to ZEN-3694 in a deal worth up to $78 million. In exchange for the expanded rights, Newsoara will pay $3.5 million upfront plus buy 1.5 million Zenith units for $1 each. Each unit consists of one share and a warrant to purchase one half of a share. Each full share will cost $1. Zenith is located in Calgary, Alberta. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital